Evidence map›Paper›PMID 30541482›Full record

ArticleBMC nephrology2018

A rare case of Alport syndrome, atypical hemolytic uremic syndrome and Pauci-immune crescentic glomerulonephritis.

Jianling Tao, Jonathan Lieberman, Richard A Lafayette, Neeraja Kambham

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. FHR-5 Serum Levels andFrontiers in immunology · 2021
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jianling TaoDepartment of Medicine, Division of Nephrology, Stanford University, Stanford, USA.
Jonathan LiebermanDepartment of Nephrology, Kaiser Permanente, San Francisco, CA, USA.
Richard A LafayetteDepartment of Medicine, Division of Nephrology, Stanford University, Stanford, USA.
Neeraja KambhamDepartment of Pathology, Stanford University, Stanford, CA, USA. neeraja.kambham@stanford.edu.
Stanford University · USKaiser Permanente San Francisco Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRenal thrombotic microangiopathy (TMA) is occasionally seen in biopsies with pauci-immune necrotizing crescentic glomerulonephritis (PCGN). Recent study indicated that the complement activation is more prominent in the ANCA-negative glomerulonephritis. CASE PRESENTATION: We report a case of concurrent TMA and PCGN without ANCA positivity. Interestingly, our patient also had biopsy features supportive of Alport syndrome (AS). Genetic studies identified variants and polymorphisms in alternative complement pathway genes that confer substantial risk of developing atypical hemolytic uremic syndrome (aHUS).

conclusionsAbnormal activation in complement pathway may represent a common pathogenic link between these three distinct entities.

Indexed as

AdultAntibodies, Antineutrophil CytoplasmicAtypical Hemolytic Uremic SyndromeComplement Pathway, ClassicalFemaleGlomerulonephritisHumansKidneyNephritis, HereditaryAntibodies, Antineutrophil CytoplasmicAlternative complement pathwayAtypical hemolytic uremic syndromePauci-immune glomerulonephritisThrombotic microangiopathy

Identifiers

PMID30541482
PMCPMC6291978
OpenAlexW2904796732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.